Cargando…

Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy

[Image: see text] Pharmaceutical scientists are increasingly interested in amorphous drug formulations especially because of their higher dissolution rates. Consequently, the thorough characterization and analysis of these formulations are becoming more and more important for the pharmaceutical indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rautaniemi, Kaisa, Vuorimaa-Laukkanen, Elina, Strachan, Clare J., Laaksonen, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150724/
https://www.ncbi.nlm.nih.gov/pubmed/29584954
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00117
_version_ 1783357046551216128
author Rautaniemi, Kaisa
Vuorimaa-Laukkanen, Elina
Strachan, Clare J.
Laaksonen, Timo
author_facet Rautaniemi, Kaisa
Vuorimaa-Laukkanen, Elina
Strachan, Clare J.
Laaksonen, Timo
author_sort Rautaniemi, Kaisa
collection PubMed
description [Image: see text] Pharmaceutical scientists are increasingly interested in amorphous drug formulations especially because of their higher dissolution rates. Consequently, the thorough characterization and analysis of these formulations are becoming more and more important for the pharmaceutical industry. Here, fluorescence-lifetime-imaging microscopy (FLIM) was used to monitor the crystallization of an amorphous pharmaceutical compound, indomethacin. Initially, we identified different solid indomethacin forms, amorphous and γ- and α-crystalline, on the basis of their time-resolved fluorescence. All of the studied indomethacin forms showed biexponential decays with characteristic fluorescence lifetimes and amplitudes. Using this information, the crystallization of amorphous indomethacin upon storage in 60 °C was monitored for 10 days with FLIM. The progress of crystallization was detected as lifetime changes both in the FLIM images and in the fluorescence-decay curves extracted from the images. The fluorescence-lifetime amplitudes were used for quantitative analysis of the crystallization process. We also demonstrated that the fluorescence-lifetime distribution of the sample changed during crystallization, and when the sample was not moved between measuring times, the lifetime distribution could also be used for the analysis of the reaction kinetics. Our results clearly show that FLIM is a sensitive and nondestructive method for monitoring solid-state transformations on the surfaces of fluorescent samples.
format Online
Article
Text
id pubmed-6150724
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-61507242018-09-24 Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy Rautaniemi, Kaisa Vuorimaa-Laukkanen, Elina Strachan, Clare J. Laaksonen, Timo Mol Pharm [Image: see text] Pharmaceutical scientists are increasingly interested in amorphous drug formulations especially because of their higher dissolution rates. Consequently, the thorough characterization and analysis of these formulations are becoming more and more important for the pharmaceutical industry. Here, fluorescence-lifetime-imaging microscopy (FLIM) was used to monitor the crystallization of an amorphous pharmaceutical compound, indomethacin. Initially, we identified different solid indomethacin forms, amorphous and γ- and α-crystalline, on the basis of their time-resolved fluorescence. All of the studied indomethacin forms showed biexponential decays with characteristic fluorescence lifetimes and amplitudes. Using this information, the crystallization of amorphous indomethacin upon storage in 60 °C was monitored for 10 days with FLIM. The progress of crystallization was detected as lifetime changes both in the FLIM images and in the fluorescence-decay curves extracted from the images. The fluorescence-lifetime amplitudes were used for quantitative analysis of the crystallization process. We also demonstrated that the fluorescence-lifetime distribution of the sample changed during crystallization, and when the sample was not moved between measuring times, the lifetime distribution could also be used for the analysis of the reaction kinetics. Our results clearly show that FLIM is a sensitive and nondestructive method for monitoring solid-state transformations on the surfaces of fluorescent samples. American Chemical Society 2018-03-27 2018-05-07 /pmc/articles/PMC6150724/ /pubmed/29584954 http://dx.doi.org/10.1021/acs.molpharmaceut.8b00117 Text en Copyright © 2018 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Rautaniemi, Kaisa
Vuorimaa-Laukkanen, Elina
Strachan, Clare J.
Laaksonen, Timo
Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title_full Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title_fullStr Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title_full_unstemmed Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title_short Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy
title_sort crystallization kinetics of an amorphous pharmaceutical compound using fluorescence-lifetime-imaging microscopy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150724/
https://www.ncbi.nlm.nih.gov/pubmed/29584954
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00117
work_keys_str_mv AT rautaniemikaisa crystallizationkineticsofanamorphouspharmaceuticalcompoundusingfluorescencelifetimeimagingmicroscopy
AT vuorimaalaukkanenelina crystallizationkineticsofanamorphouspharmaceuticalcompoundusingfluorescencelifetimeimagingmicroscopy
AT strachanclarej crystallizationkineticsofanamorphouspharmaceuticalcompoundusingfluorescencelifetimeimagingmicroscopy
AT laaksonentimo crystallizationkineticsofanamorphouspharmaceuticalcompoundusingfluorescencelifetimeimagingmicroscopy